RESUMO
Background: Breast cancer is the most common malignancy in women. Breast Cancer Type 1 Susceptibility gene [BRCA1] is a tumor suppressor gene, involved in DNA damage repair and in 81% of the breast-ovarian cancer families were due to BRCA1. In some clinically investigated genes, the intragenic marker polymorphism is important and the screening of such mutations is faster by using short tandem repeat [STR] polymorphism. Individual polymorphism of STR is a good evidence for following inheritance of repeat polymorphism
Objective: The aim of this study was to evaluate three intragenic BRCA1 marker polymorphisms in families, which have two or more patients with breast/ovarian cancer in comparison to healthy women
Materials and Methods: A total of 107 breast and/or ovarian cancer patients and 93 unrelated healthy women with no clinical phenotype of any malignancy or familial cancer history constitute the study groups. Haplotyping analysis, at 3 intragenic BRCA1 microsatellite markers [D17S855, D17S1322 and D17S1323], were performed for all subject and control groups using labeled primers
Results: After fragment analysis, significance differences were observed as follows: two alleles of D17S855; allele 146 [p=0.02] and 150 [p=0.006], and two alleles of D17S1322, allele 121 [p=0.015] and 142 [p=0.043]. These differences were compared with control group. There was significance difference in 8 di/tri allelic haplotypes in present experimental subjects. Some haplotypes were observed to have approximately twice the relation risk for breast cancer
Conclusion: According to recent results, assessment of presence or absence of mentioned alleles in BRCA1 microsatellite can be used for prognosis in individuals, suspected of having or not having the breast cancer